Plain-English translation of NCT07474324 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether disitamab vedotin (a targeted cancer drug) combined with standard chemotherapy works better than chemotherapy alone after surgery for advanced stomach cancer. The study focuses on patients whose cancer cells have moderate-to-high levels of a protein called HER2. About 124 people will participate across multiple hospitals.
Stage III stomach cancer has a high risk of coming back after surgery, even with chemotherapy alone. Researchers want to see if adding this new targeted medication can improve outcomes by attacking cancer cells in a different way.
You likely qualify if…
You likely don't qualify if…
After surgery, you would receive 6 to 8 cycles of treatment over several months, either the new medication plus chemotherapy or chemotherapy alone. You would visit the hospital regularly for drug infusions and blood tests. After treatment ends, you would have imaging scans every three months for the first period, and follow-up visits would continue for years to watch for any signs of cancer returning.
AI-generated summary from trial data · Jun 13, 2026 · Not medical advice
China